Various treatments for dry eye disease are navigated with regard to both payer and provider considerations.

Dr Periman addresses cost-related concerns associated with treating dry eye disease.

Quality-of-life concerns, including biopsychosocial impacts caused by dry eye disease, are explored by Dr Periman.

Dr Laura Periman, MD illustrates the current risk factors and prevalence regarding patients with dry eye disease.

Dr Bhatia concludes our discussion by outlining what factors physicians should be cognizant of when prescribing therapies to patients with AD.

A dermatology expert highlights the role JAK inhibitors play in AD therapy, from mechanism of action to ruxolitinib and the TrUE AD1 and -2 trials.

Dr Neal Bhatia explains the available treatment options for patients with AD, including their relation to guideline recommendations.

Neal Bhatia, MD, provides an overview of atopic dermatitis (AD) and the diagnostic process, as well as how its severity impacts the patient.

Drs Al-Hendy and Lopes conclude with final thoughts on GnRH receptor antagonists, relugolix and elagolix, changing the UF treatment landscape.